"Waitlist mortality" is high for myeloma patients with limited access to BCMA therapy.

Nausheen Ahmed,William Wesson,Muhammad Umair Mushtaq,Rajat Bansal,Haitham AbdelHakim,Sarah Bromert,Allison Appenfeller, Batool Abu Ghazal,Anurag Singh,Sunil Abhyankar,Siddhartha Ganguly,Joseph McGuirk,Al-Ola Abdallah,Leyla Shune

Frontiers in oncology（2023）

引用 0|浏览17

暂无评分

摘要

Many patients who were eligible for ide-cel were not able to secure a timely slot in 2021. Mortality was higher in this group, due to a lack of comparable alternatives. Increasing alternate options as well as improvement in manufacturing and access is an area of high importance to improve RRMM outcomes.

查看译文

关键词

myeloma patients,waitlist mortality”

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要